Resources (2)

Apr 16, 2026

FRONTEO and Astellas Pharma Sign Agreement for Target Molecule Discovery

“Drug Discovery AI Factory,” AI-based drug discovery support service, enables discontinuous discovery of new target molecules, paving the way for the early creation of innovative pharmaceuticals

Mar 31, 2026

FRONTEO and Keio University School of Medicine Have Been Granted Two Patents for a Conversational AI Program to Support Depression Diagnosis

The system assesses depressive symptoms based on approximately 10 minutes of free conversation; designed for use in a variety of medical and healthcare settings, including telemedicine and health screenings, it aims to address the treatment gap.

“TalkLab KIBIT,” a web application that uses AI analysis to assess “Brain Health Score” through conversation, has launched as part of Asahi Life's “Everyone's Peace of Mind 100-Year Project.”のサムネイル

Mar 26, 2026

TalkLab KIBIT,” a web application that uses AI analysis to assess “Brain Health Score” through conversation, has launched as part of Asahi Life Insurance's “Everyone's Peace of Mind 100-Year Project.”

Mar 5, 2026

FRONTEO Expands Reach of “Brain Health Score” Through Local Government Partnerships; Offers Hands-On Experience with “TalkLab KIBIT” in Gamagori City

Feb 18, 2026

FRONTEO and Nippon Kayaku Launch Co-creation Project Aimed at Maximizing the Value of Nippon Kayaku’s Drug Discovery Assets

By utilizing the “Drug Discovery AI Factory”—which discontinuously and systematically identifies previously unknown associations between diseases and target molecules based on existing literature—the companies aim to maximize the value of Nippon Kayaku’s drug discovery assets.

Feb 16, 2026

FRONTEO and Maruishi Pharmaceutical Enter into Strategic Business Alliance Agreement for Drug Discovery Research and Development

Agreement reached on a new contract model to comprehensively support enterprise -wide drug discovery strategies beyond specific diseases/research areas by leveraging the AI drug discovery support service “Drug Discovery AI Factory,” and to share future outcomes.

Feb 12, 2026

FRONTEO Launches “DDAIF Innovation Bridge” to Provide Scientific Support for Bio-Ventures Through Its AI-Driven Drug Discovery Support Service “Drug Discovery AI Factory”

Feb 12, 2026

FRONTEO and NB Health Laboratory Reach a Basic Agreement on Joint Research in GPCR Antibody Drug Discovery

Aiming for implementation as early as FY2026 to secure discontinuous revenue opportunities

Feb 5, 2026

FRONTEO and GlyTech Launch Proof-of-Concept (PoC) for AI-Driven Drug Discovery

Utilizing Drug Discovery AI Factory—which systematically identifies previously unknown correlations between diseases and target molecules based on existing literature—to explore new target molecules and indications for glycan-modification-based drug discovery

Feb 3, 2026

FRONTEO and C4U Conclude a PoC Agreement to Establish a New Drug Discovery Approach Combining “Drug Discovery AI Factory” and Next-Generation Genome Editing Technology

Jan 21, 2026

FRONTEO and TAGCyx Bio concluded a PoC feasibility agreement to explore new therapeutic targets and indications for artificial nucleic acid aptamers utilizing Drug Discovery AI Factory

Jan 7, 2026

FRONTEO and CellAxia Conclude a PoC Agreement to Improve Manufacturing Efficiency and Cellular Function of Cell Therapy Products Using Drug Discovery AI Factory

1 2 3 4 5